Sanofi CHC sales up 9% in Q1 driven by addition of US healthy aging supplement brand Qunol. Separately, the Paris-based firm has reached an agreement in principle to resolve the vast majority of Zantac personal injury state court cases in the US.

R&D investments behind consumer health brands such as Nurofen and Durex pay off for Reckitt in Q1 as it sees volume growth across majority of portfolio.

Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.

Major Europe-based consumer health players Reckitt, Sanofi, Haleon and Bayer feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q1 2024 results over the coming weeks.

Virus-blocking compound Carragelose, out-licensed to major consumer health players such as Perrigo and Reckitt for use in OTC respiratory nasal sprays, is being adapted for use in the dry eye and allergy categories.

Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.